Peptide reference
PEG-MGF
Pegylated Mechano Growth Factor ·PEGylated MGF ·Mechano Growth Factor PEG ·MGF (PEGylated) ·IGF-1Ec PEGylated analog
What cited sources report about PEG-MGF
PEG-MGF is a polyethylene-glycol-conjugated synthetic peptide derived from the E-domain of the IGF-1Ec splice variant — the human transcript also called Mechano Growth Factor (MGF). The E-domain is a short C-terminal sequence that arises from alternative splicing of the IGF-1 gene in mechanically loaded muscle. PEGylation is a chemical modification routinely applied to therapeutic peptides to extend serum half-life. As of the cited literature, no PEGylated MGF product has been characterized in a published clinical trial, no marketing authorization exists in any major jurisdiction, and the peptide is currently under FDA Pharmacy Compounding Advisory Committee (PCAC) review with a public meeting scheduled for February 1, 2027. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Kandalla et al. (2011) — Mechanisms of Ageing and Development
A study from the Institut de Myologie (Paris) and University College London examined the effect of a synthetic MGF E-peptide on cultured human satellite cells obtained from donors across a range of ages. The authors reported that MGF-E increased the proliferative life span of satellite cells from younger donors and delayed replicative senescence in those cultures, while no equivalent effect was observed in cells from older donors. The study used unmodified (non-PEGylated) E-peptide and was conducted entirely in vitro.
MGF E peptide has a marked ability to enhance satellite cell activation, proliferation and fusion.
Vassilakos et al. (2014) — Hormones (Athens)
A review from the Department of Experimental Physiology at the National and Kapodistrian University of Athens surveyed the biological activity of the IGF-1Ec E-domain as addressed by published synthetic-peptide experiments. The authors noted that IGF-1Ec/MGF is preferentially up-regulated after skeletal-muscle injury and post-infarct myocardial remodelling, and that all biological characterizations to date had relied on a 24-amino-acid synthetic peptide analogue tested in preclinical systems. No human pharmacokinetic, safety, or efficacy data — for either unmodified MGF or any PEGylated variant — were cited.
The biological activity of the E domain of the IGF-1Ec isoform has been evaluated by using a 24 amino acid synthetic peptide analogue.
Armakolas et al. (2016) — Critical Reviews in Oncology/Hematology
A critical review from the University of Athens catalogued published expression data and bioactivity reports for the IGF-1Ec/MGF isoform across skeletal muscle, bone, and osteosarcoma. The authors described the Ec peptide as a candidate for further therapeutic investigation in myoskeletal repair and oncology, while noting that no IGF-1Ec or MGF preparation — PEGylated or otherwise — had advanced into a registered human trial. The review concentrates on rodent and cell-culture evidence.
Growth hormone (GH) regulated mainly liver-produced insulin-like growth factor 1 (IGF-1) is a key molecule in embryonic & post embryonic development that is also involved in cancer biology.
PubChem — National Center for Biotechnology Information
PubChem aggregates compound records for synthetic E-peptide analogues of IGF-1Ec (mechano growth factor), corresponding to the 24-residue C-terminal sequences used in the preclinical literature. The database does not, as of the date of this page, list a discrete compound record for a PEGylated MGF product, consistent with the absence of a registered drug substance in any pharmacopoeia.
PubChem search: mechano growth factor ↗
Coverage notes
The published MGF literature consists almost entirely of preclinical work on the unmodified synthetic E-peptide; “PEG-MGF” as a product name appears almost exclusively in marketing copy from research-chemical and grey-market vendors rather than in indexed peer-reviewed clinical literature. Independent reviewers (Vassilakos 2014, Armakolas 2016) have noted the absence of human pharmacokinetic or efficacy studies. No FDA-approved indication exists, no FDA briefing document is publicly indexed under the PCAC archive at the time this page was compiled, and no PEGylated MGF preparation has been characterized in any record on ClinicalTrials.gov. This page will be updated when the February 2027 PCAC briefing materials are released.